Literature DB >> 9161559

[Raynaud syndrome complicated by digital gangrene during treatment with interferon-alpha].

E Liozon1, L Delaire, P Lacroix, F Labrousse, K Ly, A L Fauchais, V Loustaud-Ratti, J Vidal, F Liozon, E Vidal.   

Abstract

In a 43-year old male suffering from idiopathic hypereosinophilic syndrome (HES) since 1984, successfully treated with alpha interferon (alpha IFN) for 32 months, a severe Raynaud's phenomenon of the four extremities occurred and eventually evolved into digital necrosis within a few weeks. The arterial echography/doppler and plethysmography patterns were suggestive of isolated small-to medium-size digital artery occlusions. An extensive search for an aetiology of digital necrosis, including complete tests of autoimmunity, remained negative. Two months later, despite alpha IFN withdrawal and intravenous infusions of ilomedin, the digital ischemia evolved to extensive necrosis that necessitated several amputations and a definitive spinal chord stimulation. Pathologic examination of arteries showed no vasculitis but diffuse arterial occlusions by thrombi.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9161559     DOI: 10.1016/s0248-8663(97)84017-9

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  3 in total

Review 1.  Drug-induced vasculitis.

Authors:  Marta Lucia Cuellar
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 2.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

3.  Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma.

Authors:  H Husein-Elahmed; J L Callejas-Rubio; R Ortega Del Olmo; R Ríos-Fernandez; N Ortego-Centeno
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.